(eBook) Cardiac Markers 2nd Edition by Alan H. B. Wu

This is the PDF eBook version for Cardiac Markers 2nd Edition by Alan H. B. Wu

Table of Contents

Part I. Cardiac Markers in Clinical Practice

Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Prools

Andra L. Blomkalns and W. Brian Gibler

Management of Acute Coronary Syndromes

Constantine N. Aroney and James A. de Lemos

Evolution of Cardiac Markers in Clinical Trials

Alexander S. Ro and Christopher R. deFilippi

Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise

Robert H. Christenson and Hassan M. E. Azzazy

The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents

Eugene H. Herman, Steven E. Lipshultz, and Victor J. Ferrans

The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery

Jesse E. Adams, III

Part II. Clinical Use for Cardiac Troponins

Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications

Ralf Labugger, D. Kent Arrell, and Jennifer E. Van Eyk

Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients

Fred S. Apple

Cardiac-Specific Troponins Beyond Ischemic Heart Disease

David Morrow

Part III. Analytical Issues for Cardiac Markers

Antibody Selection Strategies in Cardiac Troponin Assays

Alexei Katrukha

Interferences in Immunoassays for Cardiac Troponin

Kiang-Teck J. Yeo and Daniel M. Hoefner

Cardiac Marker Measurement by Point-of-Care Testing

Paul O. Collinson

Standardization of Cardiac Markers

Mauro Panteghini

Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers

Alan H. B. Wu

Part IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification

Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes

Robert L. Jesse

Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin

Alan H. B. Wu, Peter Crosby, Gary Fagan, Oliver Danne, Ulrich Frei, Martin Möckel, and Joseph Keffer

C-Reactive Protein for Primary Risk Assessment

Gavin J. Blake and Paul M. Ridker

Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes

Luigi M. Biasucci, Antonio Abbate, and Giovanna Liuzzo

Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement

Thomas B. Ledue and Nader Rifai

Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification

Jan F. C. Glatz, Roy F. M. van der Putten, and Wim T. Hermens

Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease

Paul Holvoet

Part V. Cardiac Markers of Congestive Heart Failure

Pathophysiology of Heart Failure

Johannes Mair

B-Type Natriuretic Peptide: Biochemistry and Measurement

Jeffrey R. Dahlen

B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure

Ramin Tabbibizar and Alan Maisel

Monitoring Efficacy of Treatment with Brain Natriuretic Peptide

Emil D. Missov and Leslie W. Miller

N-Terminal Pro-B-Type Natriuretic Peptide

Torbjørn Omland and Christian Hall

Part VI. Role of Infectious Diseases and Genetics in Heart Disease

Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae

Martin Möckel

Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics

Alan H. B. Wu

Index